Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
Tóm tắt
Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the standard of care for TNBC treatment, but unfortunately, patients frequently develop resistance. Accordingly, in recent years, tremendous effort has been made into elucidating the mechanisms of TNBC chemoresistance with the goal of identifying new molecular targets. It has become evident that the development of TNBC chemoresistance is multifaceted and based on the elaborate interplay of the tumor microenvironment, drug efflux, cancer stem cells, and bulk tumor cells. Alterations of multiple signaling pathways govern these interactions. Moreover, TNBC’s high heterogeneity, highlighted in the existence of several molecular signatures, presents a significant obstacle to successful treatment. In the present, in-depth review, we explore the contribution of key mechanisms to TNBC chemoresistance as well as emerging strategies to overcome them. We discuss novel anti-tumor agents that target the components of these mechanisms and pay special attention to their current clinical development while emphasizing the challenges still ahead of successful TNBC management. The evidence presented in this review outlines the role of crucial pathways in TNBC survival following chemotherapy treatment and highlights the importance of using combinatorial drug strategies and incorporating biomarkers in clinical studies.
Từ khóa
Tài liệu tham khảo
Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492
Siddharth, S., and Sharma, D. (2018). Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. Cancers, 10.
Dent, 2007, Triple-negative breast cancer: Clinical features and patterns of recurrence, Clin. Cancer Res., 13, 4429, 10.1158/1078-0432.CCR-06-3045
Kennecke, 2010, Metastatic behavior of breast cancer subtypes, J. Clin. Oncol., 28, 3271, 10.1200/JCO.2009.25.9820
Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci. USA, 98, 10869, 10.1073/pnas.191367098
Prat, 2013, Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer, Oncologist, 18, 123, 10.1634/theoncologist.2012-0397
Prat, 2010, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res., 12, R68, 10.1186/bcr2635
Lebert, 2018, Advances in the systemic treatment of triple-negative breast cancer, Curr. Oncol., 25, S142, 10.3747/co.25.3954
Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J. Clin. Oncol., 26, 1275, 10.1200/JCO.2007.14.4147
Carey, 2007, The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes, Clin. Cancer Res., 13, 2329, 10.1158/1078-0432.CCR-06-1109
Sissung, 2010, Pharmacogenetics of membrane transporters: An update on current approaches, Mol. Biotechnol., 44, 152, 10.1007/s12033-009-9220-6
Sharom, 2008, ABC multidrug transporters: Structure, function and role in chemoresistance, Pharmacogenomics, 9, 105, 10.2217/14622416.9.1.105
Yamada, 2013, High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival, Breast Cancer Res. Treat., 137, 773, 10.1007/s10549-012-2398-5
Xu, 2017, Expression of aldehyde dehydrogenase 1 and ATP-binding cassette superfamily G member 2 is enhanced in primary foci and metastatic lymph node from patients with triple-negative breast cancer, Biomed. Res., 28, 5078
Guestini, 2019, Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy, Breast Cancer Res. Treat., 173, 275, 10.1007/s10549-018-4985-6
Das, 2013, Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition, J. Biol. Chem., 288, 11824, 10.1074/jbc.M112.432302
Britton, 2012, Breast cancer, side population cells and ABCG2 expression, Cancer Lett., 323, 97, 10.1016/j.canlet.2012.03.041
Arumugam, 2019, Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2, Exp. Mol. Med., 51, 2, 10.1038/s12276-018-0197-8
Oguri, 2007, MRP8/ABCC11 directly confers resistance to 5-fluorouracil, Mol. Cancer Ther., 6, 122, 10.1158/1535-7163.MCT-06-0529
Hamed, 2019, Targeting multidrug resistance in cancer by natural chemosensitizers, Bull. Natl. Res. Cent., 43, 8, 10.1186/s42269-019-0043-8
Heenan, 2004, Increased Anti-tumour Efficacy of Doxorubicin when Combined with Sulindac in a Xenograft Model of an MRP-1-positive Human Lung Cancer, Anticancer Res., 24, 457
Ballot, 2007, A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer, Cancer Chemother. Pharmacol., 59, 79
Peng, H., Dong, Z., Qi, J., Yang, Y., Liu, Y., Li, Z., Xu, J., and Zhang, J.-T. (2009). A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS ONE, 4.
Wu, 2018, Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells, Mol. Cancer, 17, 25, 10.1186/s12943-018-0775-3
Nakai, 2016, A perspective on anti-EGFR therapies targeting triple-negative breast cancer, Am. J. Cancer Res., 6, 1609
Zhu, 2015, The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer, Front. Endocrinol., 6, 159, 10.3389/fendo.2015.00159
Wang, 2017, Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance, Oncotarget, 8, 111281, 10.18632/oncotarget.22781
Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429
Deng, T., Xie, N., Mou, L., Jin, Y., Hu, Z., Li, Z., Liu, W., and Yuan, J. (2014). Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference. PLoS ONE, 9.
Hu, 2017, Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells, J. Huazhong Univ. Sci. Technol.-Med. Sci., 37, 231, 10.1007/s11596-017-1720-1
Su, 2016, Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy, Am. J. Transl. Res., 8, 2790
Wang, 2016, miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells, Gynecol. Oncol., 141, 592, 10.1016/j.ygyno.2015.11.034
Westover, 2015, FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance, Mol. Cancer, 14, 1, 10.1186/s12943-015-0362-9
Ling, 2015, Fl118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models, Am. J. Transl. Res., 7, 1765
Shibata, M., and Hoque, M.O. (2019). Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. Cancers, 11.
Khan, A.Q., Ahmed, E.I., Elareer, N.R., Junejo, K., Steinhoff, M., and Uddin, S. (2019). Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. Cells, 8.
Creighton, 2009, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc. Natl. Acad. Sci. USA, 106, 13820, 10.1073/pnas.0905718106
Lee, 2011, An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer, Br. J. Cancer, 104, 1730, 10.1038/bjc.2011.159
Park, 2010, Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer, Clin. Cancer Res., 16, 876, 10.1158/1078-0432.CCR-09-1532
Ma, 2014, Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC), Cancer Lett., 353, 153, 10.1016/j.canlet.2014.06.022
Ma, 2017, Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC), Medicine, 96, 1
Wang, 2017, CD44+/CD24- phenotype predicts a poor prognosis in triple-negative breast cancer, Oncol. Lett., 14, 5890
Bhola, 2013, TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer, J. Clin. Invest., 123, 1348, 10.1172/JCI65416
Samanta, 2014, Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells, Proc. Natl. Acad. Sci. USA, 111, E5429, 10.1073/pnas.1421438111
He, 2019, Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy, Cell Death Dis., 10, 285, 10.1038/s41419-019-1512-6
Zhou, 2001, The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype, Nat. Med., 7, 1028, 10.1038/nm0901-1028
Shishido, 2013, ABCG2 inhibitor YHO-13351 sensitizes cancer stem/Initiating-like side population cells to irinotecan, Anticancer Res., 33, 1379
Yang, C., He, Y., Zhang, H., Liu, Y., Wang, W., Du, Y., and Gao, F. (2015). Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo. Oncotarget, 6.
He, 2016, Nanomedicine-mediated therapies to target breast cancer stem cells, Front. Pharmacol., 7, 1, 10.3389/fphar.2016.00313
Smith, 2012, Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy, Clin. Cancer Res., 18, 4514, 10.1158/1078-0432.CCR-11-3224
Neuzillet, 2015, Targeting the TGFβ pathway for cancer therapy, Pharmacol. Ther., 147, 22, 10.1016/j.pharmthera.2014.11.001
Asiedu, 2011, TGFβ/TNFα-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype, Cancer Res., 71, 4707, 10.1158/0008-5472.CAN-10-4554
Xu, 2018, TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis, Biochem. Biophys. Res. Commun., 502, 160, 10.1016/j.bbrc.2018.05.139
Giaccone, 2015, A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer, Eur. J. Cancer, 51, 2321, 10.1016/j.ejca.2015.07.035
Bogdahn, 2011, Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study, Neuro. Oncol., 13, 132, 10.1093/neuonc/noq142
Aster, 2017, The Varied Roles of Notch in Cancer, Annu. Rev. Pathol. Mech. Dis., 12, 245, 10.1146/annurev-pathol-052016-100127
Rustighi, 2014, Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast, EMBO Mol. Med., 6, 99, 10.1002/emmm.201302909
Harrison, 2010, Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor, Cancer Res., 70, 709, 10.1158/0008-5472.CAN-09-1681
Nagamatsu, 2014, NOTCH4 is a potential therapeutic target for triple-negative breast cancer, Anticancer Res., 34, 69
Diluvio, 2018, NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest, Oncogenesis, 7, 42, 10.1038/s41389-018-0051-9
Zang, S., Chen, F., Dai, J., Guo, D., Tse, W., Qu, X., Ma, D., and Ji, C. (2010). RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol. Rep., 23.
Choy, 2017, Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers, Cancer Res., 77, 1439, 10.1158/0008-5472.CAN-16-1022
Zhang, 2016, Notch3 inhibits epithelial–mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells, Oncogenesis, 5, e269, 10.1038/oncsis.2016.67
Kim, B., Stephen, S.L., Hanby, A.M., Horgan, K., Perry, S.L., Richardson, J., Roundhill, E.A., Valleley, E.M.A., Verghese, E.T., and Williams, B.J. (2015). Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer, 15.
Li, 2015, Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells, Int. J. Clin. Exp. Pathol., 8, 4378
Qiu, 2013, Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells, Cancer Lett., 328, 261, 10.1016/j.canlet.2012.09.023
Locatelli, 2017, Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer, Oncotarget, 8, 2320, 10.18632/oncotarget.13727
Schott, 2013, Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors, Clin. Cancer Res., 19, 1512, 10.1158/1078-0432.CCR-11-3326
Broner, 2019, AL101 mediated tumor inhibition in notch-altered TNBC PDX models, J. Clin. Oncol., 37, 1064, 10.1200/JCO.2019.37.15_suppl.1064
Smith, 2019, A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors, Invest. New Drugs, 37, 722, 10.1007/s10637-018-0714-6
Ng, L.F., Kaur, P., Bunnag, N., Suresh, J., Sung, I.C.H., Tan, Q.H., Gruber, J., and Tolwinski, N.S. (2019). WNT Signaling in Disease. Cells, 8.
Duchartre, 2016, The Wnt signaling pathway in cancer, Crit. Rev. Oncol. Hematol., 99, 141, 10.1016/j.critrevonc.2015.12.005
Dey, N., Barwick, B.G., Moreno, C.S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G., Tang, W., Catzavelos, C., Kerstann, K.F., and Sledge, G.W. (2013). Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer, 13.
Xu, J., Prosperi, J.R., Choudhury, N., Olopade, O.I., and Goss, K.H. (2015). β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS ONE, 10.
Shen, 2019, Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin, J. Exp. Clin. Cancer Res., 38, 243, 10.1186/s13046-019-1231-y
Corda, 2017, Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer, J. Pathol., 241, 350, 10.1002/path.4841
Yin, 2013, Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer, Mol. Cancer Ther., 12, 491, 10.1158/1535-7163.MCT-12-1090
Ma, 2017, Role of Wnt Co-Receptor LRP6 in Triple Negative Breast Cancer Cell Migration and Invasion, J. Cell. Biochem., 118, 2968, 10.1002/jcb.25956
Gangrade, A., Pathak, V., Augelli-Szafran, C.E., Wei, H.-X., Oliver, P., Suto, M., and Buchsbaum, D.J. (2018). Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer. Int. J. Mol. Sci., 19.
Li, 2019, Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer, Oncol. Rep., 41, 437
Jang, 2015, Wnt/-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells, Cancer Res., 75, 1691, 10.1158/0008-5472.CAN-14-2041
Ahmed, 2019, Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor, Cancer Lett., 449, 45, 10.1016/j.canlet.2019.02.018
Ha, 2018, Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells, Anticancer Res., 38, 1303
Xie, 2018, A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway, Int. J. Biochem. Cell Biol., 103, 45, 10.1016/j.biocel.2018.08.004
Skoda, 2018, The role of the Hedgehog signaling pathway in cancer: A comprehensive review, Bosn. J. basic Med. Sci., 18, 8, 10.17305/bjbms.2018.2756
Harris, 2012, Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61, Oncogene, 31, 3370, 10.1038/onc.2011.496
Kwon, 2011, Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines, Clin. Exp. Metastasis, 28, 437, 10.1007/s10585-011-9382-z
Rosa, 2017, Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers, Br. J. Cancer, 116, 1425, 10.1038/bjc.2017.116
Bhateja, P., Cherian, M., Majumder, S., and Ramaswamy, B. (2019). The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?. Cancers, 11.
Han, 2015, FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer, Cell Rep., 13, 1046, 10.1016/j.celrep.2015.09.063
Liu, 2006, Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells, Cancer Res., 66, 6063, 10.1158/0008-5472.CAN-06-0054
Opdenaker, 2015, Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy, Mol. Carcinog., 54, 1480, 10.1002/mc.22225
Lei, 2015, Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer, Tumour Biol., 36, 3119, 10.1007/s13277-014-2948-z
Arnold, 2017, Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple negative breast cancer, Oncol. Lett., 14, 5285
Machalek, 2011, Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer, Cancer Res., 71, 4002, 10.1158/0008-5472.CAN-10-3738
Koike, 2017, Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells, Breast Cancer, 24, 683, 10.1007/s12282-017-0757-0
Vaupel, 2008, Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis, Oncologist, 13, 21, 10.1634/theoncologist.13-S3-21
Gerweck, 2006, Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics, Mol. Cancer Ther., 5, 1275, 10.1158/1535-7163.MCT-06-0024
Cosse, 2008, Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression, Anticancer. Agents Med. Chem., 8, 790, 10.2174/187152008785914798
Kim, 2018, The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells, Breast Cancer Res., 20, 1, 10.1186/s13058-018-0944-8
Chouaib, 2017, Hypoxic stress: Obstacles and opportunities for innovative immunotherapy of cancer, Oncogene, 36, 439, 10.1038/onc.2016.225
Xiang, 2012, Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma, Diagn. Pathol., 7, 32, 10.1186/1746-1596-7-32
Lv, 2015, Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer, Onco. Targets. Ther., 8, 1941, 10.2147/OTT.S82835
Daskalaki, 2018, Hypoxia and Selective Autophagy in Cancer Development and Therapy, Front. Cell Dev. Biol., 6, 1, 10.3389/fcell.2018.00104
Livasy, 2006, Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma, Mod. Pathol., 19, 264, 10.1038/modpathol.3800528
Tan, 2009, The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy, Br. J. Cancer, 100, 405, 10.1038/sj.bjc.6604844
Montagner, 2012, SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors, Nature, 487, 380, 10.1038/nature11207
Chen, 2014, XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway, Nature, 508, 103, 10.1038/nature13119
Bernardi, 2014, Hallmarks of triple negative breast cancer emerging at last?, Cell Res., 24, 904, 10.1038/cr.2014.61
Jin, 2016, Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer, Virchows Arch., 469, 183, 10.1007/s00428-016-1953-6
Bharti, 2018, Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft, Oncotarget, 9, 15326, 10.18632/oncotarget.24569
Borad, 2015, Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer, J. Clin. Oncol., 33, 1475, 10.1200/JCO.2014.55.7504
Baran, 2017, Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy, Clin. Cancer Res., 23, 2382, 10.1158/1078-0432.CCR-16-0895
Ban, 2017, The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth, Cell Death Dis., 8, e2843, 10.1038/cddis.2017.235
Soni, 2017, HIF-1 in cancer therapy: Two decade long story of a transcription factor, Acta Oncol., 56, 503, 10.1080/0284186X.2017.1301680
Courtney, 2018, Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2a antagonist in patients with previously treated advanced clear cell renal cell carcinoma, J. Clin. Oncol., 36, 867, 10.1200/JCO.2017.74.2627
Hall, 2002, Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide, Breast Cancer Res. Treat., 76, 157, 10.1023/A:1020543004400
Inao, 2018, Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin, Oncotarget, 9, 25545, 10.18632/oncotarget.25370
Campbell, K.J., Dhayade, S., Ferrari, N., Sims, A.H., Johnson, E., Mason, S.M., Dickson, A., Ryan, K.M., Kalna, G., and Edwards, J. (2018). MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis., 9.
Ozretic, 2018, Apoptosis regulator bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients, Int. J. Biol. Markers, 33, 109, 10.5301/ijbm.5000291
Balko, 2014, Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets, Cancer Discov., 4, 232, 10.1158/2159-8290.CD-13-0286
Wertz, 2011, Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7, Nature, 471, 110, 10.1038/nature09779
Koff, 2015, A time to kill: Targeting apoptosis in cancer, Int. J. Mol. Sci., 16, 2942, 10.3390/ijms16022942
Merino, 2018, BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines, Cancer Cell, 34, 879, 10.1016/j.ccell.2018.11.004
Lemke, 2014, Getting TRAIL back on track for cancer therapy, Cell Death Differ., 21, 1350, 10.1038/cdd.2014.81
Greer, 2019, MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer, Breast Cancer Res., 21, 27, 10.1186/s13058-019-1116-1
Wang, 2012, Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics, J. Mammary Gland Biol. Neoplasia, 17, 217, 10.1007/s10911-012-9265-1
Bardia, 2018, Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial, J. Clin. Oncol., 36, 3126, 10.1200/JCO.2017.74.8392
Fan, 2008, Regulation of programmed cell death by NF-κB and its role in tumorigenesis and therapy, Adv. Exp. Med. Biol., 615, 223, 10.1007/978-1-4020-6554-5_11
Ossovskaya, 2011, Exploring Molecular Pathways of Triple-Negative Breast Cancer, Genes Cancer, 2, 870, 10.1177/1947601911432496
Fusella, 2017, The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis, Nat. Commun., 8, 1636, 10.1038/s41467-017-01829-1
Begalli, F., Bennett, J., Capece, D., Verzella, D., D’Andrea, D., Tornatore, L., and Franzoso, G. (2017). Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines, 5.
Messeha, 2018, The inhibitory effects of plumbagin on the NF-κB pathway and CCL2 release in racially different triple-negative breast cancer cells, PLoS ONE, 13, 1, 10.1371/journal.pone.0201116
Pan, 2012, Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway, Int. J. Mol. Med., 30, 337, 10.3892/ijmm.2012.990
Labbozzetta, 2015, Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast cancer SUM 159 cells, Oncol. Lett., 10, 3807, 10.3892/ol.2015.3787
Li, 2007, Why is PTEN an important tumor suppressor?, J. Cell. Biochem., 102, 1368, 10.1002/jcb.21593
Inanc, M., Ozkan, M., Karaca, H., Berk, V., Bozkurt, O., Duran, A.O., Ozaslan, E., Akgun, H., Tekelioglu, F., and Elmali, F. (2014). Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med. Oncol., 31.
Ueng, 2012, Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas, Int. J. Clin. Exp. Pathol., 5, 806
Steelman, 2008, Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors, Oncogene, 27, 4086, 10.1038/onc.2008.49
Choi, 2019, A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer, Gynecol. Oncol., 153, 135, 10.1016/j.ygyno.2019.01.012
Lehmann, 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J. Clin. Invest., 121, 2750, 10.1172/JCI45014
(2019, August 07). U.S. Food and Drug Administration, Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer.
Dent, 2018, Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC), J. Clin. Oncol., 36, 1008, 10.1200/JCO.2018.36.15_suppl.1008
Schmid, 2018, AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial, J. Clin. Oncol., 36, 1007, 10.1200/JCO.2018.36.15_suppl.1007
Guanizo, 2018, STAT3: A multifaceted oncoprotein, Growth Factors, 36, 1, 10.1080/08977194.2018.1473393
Hartman, 2013, Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8, Cancer Res., 73, 3470, 10.1158/0008-5472.CAN-12-4524-T
Wei, 2014, STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer, Stem Cells, 32, 2571, 10.1002/stem.1752
Sirkisoon, 2018, Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer, Oncogene, 37, 2502, 10.1038/s41388-018-0132-4
Kuo, 2017, STAT3/NF-κB-regulated lentiviral TK/GCV suicide gene therapy for cisplatin-resistant triple-negative breast cancer, Theranostics, 7, 647, 10.7150/thno.16827
Moreira, 2018, STAT3 as a promising chemoresistance biomarker associated with the CD44 +/high/CD24 -/low/ALDH + BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line, Exp. Cell Res., 363, 283, 10.1016/j.yexcr.2018.01.018
Wang, 2018, Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1α, J. Biochem. Mol. Toxicol., 32, 1, 10.1002/jbt.22039
Qin, 2019, STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review, J. Exp. Clin. Cancer Res., 38, 1, 10.1186/s13046-019-1206-z
Cheng, 2018, Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066, Int. J. Oncol., 53, 339
Abyaneh, H.S., Soleimani, A.H., Vakili, M.R., Soudy, R., Kaur, K., Cuda, F., Tavassoli, A., and Lavasanifar, A. (2018). Modulation of hypoxia-induced chemoresistance to polymeric micellar cisplatin: The effect of ligand modification of micellar carrier versus inhibition of the mediators of drug resistance. Pharmaceutics, 10.
Balko, 2016, Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence, Sci. Transl. Med., 8, ra53, 10.1126/scitranslmed.aad3001
Nascimento, 2017, Phosphoproteome profiling reveals critical role of JAK-STAT signaling in maintaining chemoresistance in breast cancer, Oncotarget, 8, 114756, 10.18632/oncotarget.21801
Park, H.S., Jang, M.H., Kim, E.J., Kim, H.J., Lee, H.J., Kim, Y.J., Kim, J.H., Kang, E., Kim, S.-W., and Kim, I.A. (2014). High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol., 1–11.
Zhang, 2014, Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients, Target. Oncol., 9, 349, 10.1007/s11523-013-0300-y
Porcelli, 2014, The EGFR pathway regulates BCRP expression in NSCLC cells: Role of erlotinib, Curr. Drug Targets, 15, 1322, 10.2174/1389450116666141205145620
Grube, 2006, EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP), Drug Metab. Dispos., 34, 524, 10.1124/dmd.105.007591
Zhang, 2018, Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo, Cancer Lett., 424, 19, 10.1016/j.canlet.2018.02.040
Baselga, 2013, Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer, J. Clin. Oncol., 31, 2586, 10.1200/JCO.2012.46.2408
Carey, 2012, TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer, J. Clin. Oncol., 30, 2615, 10.1200/JCO.2010.34.5579
Matsuda, 2018, Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer, JAMA Oncol., 4, 1207, 10.1001/jamaoncol.2018.1436
Cowherd, 2015, A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer, Cancer Biol. Ther., 16, 678, 10.1080/15384047.2015.1026481
Nabholtz, 2014, Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: Identification of biologically defined signatures predicting treatment impact, Ann. Oncol., 25, 1570, 10.1093/annonc/mdu183
Ferraro, 2013, Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR, Proc. Natl. Acad. Sci. USA, 110, 1815, 10.1073/pnas.1220763110
El Guerrab, A., Bamdad, M., Kwiatkowski, F., Bignon, Y.-J., Penault-Llorca, F., and Aubel, C. (2016). Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget, 7.
Teng, 2011, Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy, Breast Cancer Res., 13, R35, 10.1186/bcr2857
Kim, 2017, Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer, J. Breast Cancer, 20, 150, 10.4048/jbc.2017.20.2.150
Ali, 2017, The paradoxical functions of EGFR during breast cancer progression, Signal. Transduct. Target. Ther., 2, 16042, 10.1038/sigtrans.2016.42
Yuan, 2017, Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy (Review), Oncol. Lett., 15, 41
Farabaugh, S.M., Boone, D.N., and Lee, A.V. (2015). Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front. Endocrinol., 6.
Heskamp, S., Boerman, O.C., Molkenboer-Kuenen, J.D.M., Wauters, C.A., Strobbe, L.J.A., Mandigers, C.M.P.W., Bult, P., Oyen, W.J.G., van der Graaf, W.T.A., and van Laarhoven, H.W.M. (2015). Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. PLoS ONE, 10.
Litzenburger, 2011, High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy, Clin. Cancer Res., 17, 2314, 10.1158/1078-0432.CCR-10-1903
Yee, 2012, Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?, JNCI J. Natl. Cancer Inst., 104, 975, 10.1093/jnci/djs258
Ekyalongo, 2017, Revisiting the IGF-1R as a breast cancer target, NPJ Precis. Oncol., 1, 14, 10.1038/s41698-017-0017-y
Bai, 2018, MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3, Biomed. Pharmacother., 103, 1482, 10.1016/j.biopha.2018.04.165
Zhang, 2019, MicroRNA-224 Promotes Tumorigenesis through Downregulation of Caspase-9 in Triple-Negative Breast Cancer, Dis. Markers, 2019, 7378967
Liu, 2018, miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer, J. Mol. Cell Biol., 10, 302, 10.1093/jmcb/mjy041
Mao, 2017, MicroRNAs in the prognosis of triple-negative breast cancer, Medicine, 96, e7085, 10.1097/MD.0000000000007085
Song, 2018, MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD, BMB Rep., 51, 602, 10.5483/BMBRep.2018.51.11.168
Li, 2017, miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer, Breast Cancer Res., 19, 133, 10.1186/s13058-017-0918-2
Wu, 2019, Overexpression of microRNA-620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD, Exp. Ther. Med., 18, 550
Piasecka, 2018, MicroRNAs in regulation of triple-negative breast cancer progression, J. Cancer Res. Clin. Oncol., 144, 1401, 10.1007/s00432-018-2689-2
Tormo, 2019, The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors, Sci. Rep., 9, 5316, 10.1038/s41598-019-41472-y
Liu, 2019, MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2, Cell. Mol. Biol. Lett., 24, 47, 10.1186/s11658-019-0168-7
2017, A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer, Tumor Biol., 39, 101042831770289, 10.1177/1010428317702899
Petrovic, 2018, miRNAs as Potential Treatment Targets and Treatment Options in Cancer, Mol. Diagn. Ther., 22, 157, 10.1007/s40291-017-0314-8
Devulapally, 2015, Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy, ACS Nano, 9, 2290, 10.1021/nn507465d
Hashemi, 2018, Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics, Iran. J. Basic Med. Sci., 21, 427
Lehmann, B.D., Jovanović, B., Chen, X., Estrada, M.V., Johnson, K.N., Shyr, Y., Moses, H.L., Sanders, M.E., and Pietenpol, J.A. (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 11.
Burstein, 2015, Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer Analysis and interpretation of data: HHS Public Access, Clin Cancer Res., 21, 1688, 10.1158/1078-0432.CCR-14-0432
Wu, 2016, Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer, Breast Cancer Res., 18, 1
Echavarria, 2018, Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann’s Refined Classification, Clin. Cancer Res., 24, 1845, 10.1158/1078-0432.CCR-17-1912
Loibl, 2011, Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy, Breast Cancer Res. Treat., 130, 477, 10.1007/s10549-011-1715-8
Asghar, 2017, Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer, Clin. Cancer Res., 23, 5561, 10.1158/1078-0432.CCR-17-0369
Lehmann, 2014, PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors, Breast Cancer Res., 16, 406, 10.1186/s13058-014-0406-x
Tutt, 2018, Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial, Nat. Med., 24, 628, 10.1038/s41591-018-0009-7
Robson, 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, N. Engl. J. Med., 377, 523, 10.1056/NEJMoa1706450
(2019, August 22). U.S. Food and Drug Administration, Available online: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer.
Dieci, 2014, Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study, Ann. Oncol., 25, 611, 10.1093/annonc/mdt556
Schmid, 2018, Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, N. Engl. J. Med., 379, 2108, 10.1056/NEJMoa1809615
(2019, August 07). U.S. Food and Drug Administration, Available online: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative.